Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$13.72 USD

13.72
4,949,991

+1.17 (9.32%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $13.72 0.00 (0.00%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?

by Zacks Equity Research

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 80% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 500% and 5.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 3.51% and 7.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 33.33% and 2.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

by Zacks Equity Research

Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.

Zacks Equity Research

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?

by Zacks Equity Research

Here is how Acadia Healthcare (ACHC) and AxoGen (AXGN) have performed compared to their sector so far this year.

Zacks Equity Research

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline

by Zacks Equity Research

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock

by Zacks Equity Research

The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.

Zacks Equity Research

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.